Overview

Vitamin D Status in Patients With Severe Sepsis

Status:
Withdrawn
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Sepsis is a clinical entity that complicates infection. Without early recognition and timely management, it can rapidly progress to severe sepsis, septic shock, and culminate in multiple organ dysfunction syndrome. Forty to 70% of septic patients have low vitamin D status, yet little is known about the impact of vitamin D3 (vitD3) supplementation in this patient population. As such, the investigators propose a randomized, double-blinded, placebo-controlled trial to test the hypothesis that early, rapid correction of low vitamin D status, as an adjunct to established treatment guidelines, will improve clinical outcomes and measurably alter immune profile in patients with severe sepsis.
Phase:
Phase 3
Details
Lead Sponsor:
Massachusetts General Hospital
Treatments:
Cholecalciferol
Ergocalciferols
Vitamin D
Vitamins